bispecific antibodies for r/r aml: ongoing clinical trials
Published 5 years ago • 136 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
1:30
bispecific antibodies for r/r aggressive b-cell lymphomas
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
2:39
advancements in bispecific and trispecific antibodies for the treatment of lymphoma
-
1:56
the future of bispecific antibodies in the treatment and management of r/r follicular lymphoma
-
2:25
advancements and challenges in bispecific antibodies for the treatment of b-nhl
-
2:39
the role of bispecific antibodies in the treatment landscape for r/r dlbcl
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
1:23
improving the efficacy of bispecific antibodies in aml
-
1:51
how to manage tumor flare after administration of bispecific antibodies
-
1:15
the role of bispecific antibodies in the treatment of r/r large b-cell lymphoma
-
1:10
how bispecific antibodies contribute to t-cell activation in aml
-
1:54
the important role of bispecific antibodies in the future treatment of r/r dlbcl
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
0:58
first-in-human trial of cln-978, a novel cd19 bispecific antibody, for the treatment of r/r b-nhl
-
1:02
bispecific agents: the future of aml and mds treatment?
-
1:13
bisantrene for r/r aml patients
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
3:44
bispecific antibodies in b-all; blinatumomab